Terms: = Pancreatic cancer AND KLF6, RP11-184A2_1, 1316, ENSG00000067082, ST12, DKFZp686N0199, CPBP, Zf9, COPEB, ZF9, PAC1, GBF, BCD1 AND Clinical Outcome
367 results:
1. Tumor-Stroma Proportion to Predict Chemoresistance in Patients With Ovarian cancer.
Lou E; Clemente V; Grube M; Svedbom A; Nelson AC; Blome F; Staebler A; Kommoss S; Bazzaro M
JAMA Netw Open; 2024 Feb; 7(2):e240407. PubMed ID: 38411963
[TBL] [Abstract] [Full Text] [Related]
2. NAT10-mediated mRNA N4-acetylcytidine modification of MDR1 and BCRP promotes breast cancer progression.
Zhao CC; Sun X; Chen J; Geng BD
Thorac Cancer; 2024 Apr; 15(10):820-829. PubMed ID: 38409918
[TBL] [Abstract] [Full Text] [Related]
3. Locally advanced pancreatic cancer: Is surgical palliation associated with improved clinical outcome relative to medical palliation?
Kramer SP; Tonelli C; Luchette FA; Swanson J; Abdelsattar Z; Cohn T; Baker MS
Am J Surg; 2024 Apr; 230():73-77. PubMed ID: 38350746
[TBL] [Abstract] [Full Text] [Related]
4. A novel investigation into the negative impact of opioid use on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
Guo H; Li Y; Lin J; Li D; Yang J; Wang J; Mao J; Wang Y; Yan X
Int Immunopharmacol; 2024 Mar; 129():111611. PubMed ID: 38325047
[TBL] [Abstract] [Full Text] [Related]
5. Caprin-1 influences autophagy-induced tumor growth and immune modulation in pancreatic cancer.
Yang W; Chen H; Li G; Zhang T; Sui Y; Liu L; Hu J; Wang G; Chen H; Wang Y; Li X; Tan H; Kong R; Sun B; Li L
J Transl Med; 2023 Dec; 21(1):903. PubMed ID: 38082307
[TBL] [Abstract] [Full Text] [Related]
6. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract] [Full Text] [Related]
7. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
8. Cathepsin-facilitated invasion of BMI1-high hepatocellular carcinoma cells drives bile duct tumor thrombi formation.
Xu LB; Qin YF; Su L; Huang C; Xu Q; Zhang R; Shi XD; Sun R; Chen J; Song Z; Jiang X; Shang L; Xiao G; Kong X; Liu C; Wong PP
Nat Commun; 2023 Nov; 14(1):7033. PubMed ID: 37923799
[TBL] [Abstract] [Full Text] [Related]
9. Optimal Follow-up of Incidental pancreatic Cystic Lesions without Worrisome Features: clinical outcome after Long-term Follow-up.
Ahn DW; Lee SH; Choi JH; Cho IR; Jang DK; Paik WH; Jeong JB; Ryu JK; Kim YT
Gut Liver; 2024 Mar; 18(2):328-337. PubMed ID: 37840221
[TBL] [Abstract] [Full Text] [Related]
10. clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes.
Militello AM; Orsi G; Cavaliere A; Niger M; Avallone A; Salvatore L; Tortora G; Rapposelli IG; Giordano G; Noventa S; Giommoni E; Bozzarelli S; Macchini M; Peretti U; Procaccio L; Puccini A; Cascinu S; Montagna C; Milella M; Reni M
Cancer Chemother Pharmacol; 2023 Dec; 92(6):501-510. PubMed ID: 37725113
[TBL] [Abstract] [Full Text] [Related]
11. clinical outcome and therapeutic impact on neuroendocrine neoplasms of the breast: a national cancer database study.
Yang L; Lin H; Shen Y; Roy M; Albarracin C; Ding Q; Huo L; Chen H; Wei B; Bu H; Bedrosian I; Wu Y
Breast Cancer Res Treat; 2023 Nov; 202(1):23-32. PubMed ID: 37566192
[TBL] [Abstract] [Full Text] [Related]
12. Personalized cancer avatars for patients with thymic malignancies: A pilot study with circulating tumor cell-derived organoids.
Wu YH; Chao HS; Chiang CL; Luo YH; Chiu CH; Yen SH; Liu CY; Chiou JF; Burnouf T; Chen YJ; Wang PY; Chao TY; Hsu SM; Lu LS
Thorac Cancer; 2023 Sep; 14(25):2591-2600. PubMed ID: 37474689
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic value of perioperative serum low-density lipoprotein cholesterol level for postoperative prognosis of pancreatic cancer: a retrospective study.
Wang H; Li Y; Huang J; Ma Y; Lyu S; Lang R
Lipids Health Dis; 2023 Jun; 22(1):88. PubMed ID: 37391827
[TBL] [Abstract] [Full Text] [Related]
14. The Feasibility, Proficiency, and Mastery Learning Curves in 635 Robotic Pancreatoduodenectomies Following a Multicenter Training Program: "Standing on the Shoulders of Giants".
Zwart MJW; van den Broek B; de Graaf N; Suurmeijer JA; Augustinus S; Te Riele WW; van Santvoort HC; Hagendoorn J; Borel Rinkes IHM; van Dam JL; Takagi K; Tran KTC; Schreinemakers J; van der Schelling G; Wijsman JH; de Wilde RF; Festen S; Daams F; Luyer MD; de Hingh IHJT; Mieog JSD; Bonsing BA; Lips DJ; Abu Hilal M; Busch OR; Saint-Marc O; Zeh HJ; Zureikat AH; Hogg ME; Koerkamp BG; Molenaar IQ; Besselink MG;
Ann Surg; 2023 Dec; 278(6):e1232-e1241. PubMed ID: 37288547
[TBL] [Abstract] [Full Text] [Related]
15. High expression of PKCλ and ALDH1A3 indicates a poor prognosis, and PKCλ is required for the asymmetric cell division of ALDH1A3-positive cancer stem cells in PDAC.
Kasai T; Tamori S; Takasaki Y; Matsuoka I; Ozaki A; Matsuda C; Harada Y; Sasaki K; Ohno S; Akimoto K
Biochem Biophys Res Commun; 2023 Aug; 669():85-94. PubMed ID: 37267864
[TBL] [Abstract] [Full Text] [Related]
16. pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights.
Balsano R; Zanuso V; Pirozzi A; Rimassa L; Bozzarelli S
Curr Oncol; 2023 Mar; 30(4):3871-3885. PubMed ID: 37185406
[TBL] [Abstract] [Full Text] [Related]
17. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer.
Inkoom A; Ndemazie NB; Smith T; Frimpong E; Bulusu R; Poku R; Zhu X; Han B; Trevino J; Agyare E
BMC Cancer; 2023 May; 23(1):435. PubMed ID: 37179357
[TBL] [Abstract] [Full Text] [Related]
18. clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine.
D'Angelo A; Catalano M; Conca R; Petrioli R; Siminonato F; Cappetta A; Roviello G; Ramello M
J Chemother; 2023 Dec; 35(8):753-759. PubMed ID: 37167100
[TBL] [Abstract] [Full Text] [Related]
19. NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer.
Xiong Q; Zhou Y; Zhang S; Zhang Y; Xu Y; Yang Y; Zhou C; Zeng Z; Han J; Zhu Q
Cancer Med; 2023 May; 12(9):10961-10978. PubMed ID: 37062069
[TBL] [Abstract] [Full Text] [Related]
20. ScRNA-seq revealed targeting regulator of G protein signaling 1 to mediate regulatory T cells in Hepatocellular carcinoma.
Zou L; Liu K; Shi Y; Li G; Li H; Zhao C
Cancer Biomark; 2023; 36(4):299-311. PubMed ID: 36938729
[TBL] [Abstract] [Full Text] [Related]
[Next]
